Latest Breaking News On - European multidisciplinary congress - Page 1 : comparemela.com

PROfound: Phase 3 Study of Olaparib vs Enzalutamide or Abiraterone for Metastatic Castration-Resistant Prostate Cancer with Homologous Recombination Repair Gene Alterations

PROfound: Phase 3 Study of Olaparib vs Enzalutamide or Abiraterone for Metastatic Castration-Resistant Prostate Cancer with Homologous Recombination Repair Gene Alterations
urotoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from urotoday.com Daily Mail and Mail on Sunday newspapers.

United statesSan franciscoNobuaki matsubaraMaha ha hussainFred saadAntoine thiery vuilleminKim chiKarim fizaziJoaquin mateoSelena castroKimn chiOlaparib lynparzaEuropean multidisciplinary congress on urological cancersAmerican urologic associationVirtual annual meetingJohann de bono

UroToday - The Global Online Community of Urologists

UroToday - The Global Online Community of Urologists
urotoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from urotoday.com Daily Mail and Mail on Sunday newspapers.

United statesNew zealandAndrewj armstrongAndrew armstrongMichaelj morrisIan davisDavid cellaArun azadBrian riniTamim niaziBriani riniDaniel georgeThomas powlesAndrea necchiDanielj georgeMicheal morris

JAVELIN Bladder 100 Trial - Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma

JAVELIN Bladder 100 Trial Interviews with Experts at Conferences Curated by Clinicians: Educational Forum with Videos, Abstracts and Conference Information Videos April 23, 2021 November 17, 2020 November 16, 2020 October 14, 2020 Conference Coverage Conference Highlights from Recent Conference Coverage Petros Grivas, MD, PhD In Best of Podium presentation at this year’s Southeast Section of the American Urologic Association Virtual Annual Meeting, Dr. Grivas presented pre-specified subgroup analyses of the JAVELIN Bladder 100 trial. Read More Yohann Loriot, MD, PhD Avelumab first-line maintenance therapy is approved in the United States for patients with advanced urothelial carcinoma that has not progressed with first-line platinum-containing chemotherapy based on significantly prolonged overall survival versus best supportive care alone (median 21.4 months versus 14.3 months; HR 0.69, 95% CI 0.56-0.86) as reported in the phase III JAVELIN Bladder 100 tri

United statesElizabeth plimackPetros grivasShaheen alaneeJuergen gschwendMatthew galskyThomasb powlesNorihiko tsuchiyaSrikala sridharRobert dreicerYohann loriotThomas powlesEuropean society of medical oncologyEuropean multidisciplinary congress on urological cancersSociety of urologic oncologyVirtual congress

Testicular, Penile, and Rare GU Malignancies

Testicular, Penile, and Rare GU Malignancies Interviews with Experts at Conferences Curated by clinicians: educational forums with videos, abstracts and conference information Videos April 27, 2021 The State-of-the-Evidence in Brief Reviews by Experts May 17, 2021 Penile cancer (PC) is a rare malignancy with an incidence estimated less than 1/100 000 per year in the Western World 1-3 Historically, demolitive surgical approaches, such as total or partial penile amputation, were the most commonly used. Indeed, demolitive options were deemed to be necessary in order to respect a macroscopic surgical margin of at least 2 cm. 3-4 If the oncological outcomes of these approaches demonstrated to be satisfactory, they significantly affected aesthetic outcomes, as well as sexual and urinary functions.

United statesNew zealandJulien van dammePilar lagunaChristopher jd wallisFallen jamesZachary klaassenPhilippe spiessDarren feldmanAndrea necchiLucia nappiPhilippee spiessLyndal mooreJames lynamSilke gillessenPeter albers

EMUC 2020: Neoadjuvant Versus Adjuvant Strategies in Locally Advanced Bladder Cancer

EMUC 2020: Neoadjuvant Versus Adjuvant Strategies in Locally Advanced Bladder Cancer (UroToday.com) In an oral presentation in a session examining neoadjuvant versus adjuvant strategies in locally advanced bladder cancer at the 12th European Multidisciplinary Congress on Urological Cancers (EMUC), Dr. Andrea Necchi led a discussion of neoadjuvant strategies in advanced bladder cancer. He began highlighting muscle invasive bladder cancer (MIBC) as a model for clinical research based on high rates of relapse and mortality following surgical intervention alone, the relatively poor use of neoadjuvant chemotherapy in spite of international guidelines, the poor prognosis of patients with residual MIBC following neoadjuvant chemotherapy, and the uncertainty of treatment approaches in patients who are ineligible for cisplatin.

Christopher jd wallisNeoadjuvant pembrolizumabAndrea necchiEuropean multidisciplinary congress on urological cancersVanderbilt university medical centerEuropean multidisciplinary congressUrological cancersMuscle invasive urothelial bladder carcinomaNeo adjuvant bladder urothelial carcinomaMedical oncologistItaly writtenUrologic oncology fellowகிறிஸ்டோபர் ஜ்ட் வாலிஸ்ஆண்ட்ரியா னேக்சிஐரோப்பிய பலதரப்பட்ட காங்கிரஸ் ஆன் சிறுநீரக புற்றுநோய்கள்வாண்டர்பில்ட் பல்கலைக்கழகம் மருத்துவ மையம்